Edgewise Therapeutics (EWTX) Operating Expenses (2020 - 2026)

Edgewise Therapeutics (EWTX) has 7 years of Operating Expenses data on file, last reported at $54.1 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 17.75% year-over-year to $54.1 million; the trailing twelve-month figure through Mar 2026 stood at $199.6 million (up 17.36% YoY), and the FY2025 full-year result was $191.4 million, up 20.51% from the prior year.
• Operating Expenses slipped to $54.1 million in Q1 2026, from $56.0 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $56.0 million in Q4 2025 to a low of $14.8 million in Q1 2022.
• A 5-year average of $34.7 million and a median of $34.8 million in 2024 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses surged 116.22% in 2022 and rose 11.82% in 2025, its largest moves.
• Tracing EWTX's Operating Expenses over 5 years: stood at $22.1 million in 2022, then surged by 53.37% to $33.9 million in 2023, then surged by 34.49% to $45.5 million in 2024, then grew by 22.92% to $56.0 million in 2025, then decreased by 3.33% to $54.1 million in 2026.
• Business Quant data shows EWTX's Operating Expenses at $54.1 million in Q1 2026, $56.0 million in Q4 2025, and $46.9 million in Q3 2025.